Novo Nordisk's
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
Novo Nordisk is launching its weight loss pill Wegovy in the United Arab Emirates, the Danish drugmaker said Wednesday, marking its first launch outside the U.S. market. Novo's approach will be guided by patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure, said Emil Kongshøj Larsen, executive vice president, International Operations. "The UAE has demonstrated strong momentum across all of these areas, and we look forward to...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Pill from drugmaker would put it into competition with market leaders Novo Nordisk and Eli Lilly
Ozempic-like drugs may improve kidney disease outcomes: study
Semaglutide and Ozempic-like drugs may improve kidney disease outcomes Wed 3 Jun 2026 at 5:00am In short: New research shows people with type 2 diabetes and chronic kidney disease who took semaglutide (commonly sold as Ozempic) once a week had improved kidney outcomes, even if they have heart disease or heart failure. This builds on previous research which found the drug had "consistent benefits" preventing heart attacks, strokes, and death due to cardiovascular causes in those with chronic...
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
Eli Lilly 's expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to record highs. "It's a parabolic spike. I don't buy parabolas," Jim Cramer said on " Squawk on the Street " on Monday.
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...
Trump expands TrumpRx prescription drug discount program to more than 800 medications
President Donald Trump on Friday announced a major expansion of his administration's initiative aimed at helping Americans access discounted prescription medications. In a Truth Social post, Trump said the government-backed website TrumpRx.gov has added 160 prescription drugs, bringing the total number of discounted medications available through the program to more than 800."I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a...
Mutation-dependent responses to sleep and exercise in clonal haematopoiesis
Abstract Clonal haematopoiesis (CH) activates inflammation and increases the risk of atherosclerosis1,2. Whether lifestyle alters CH clone expansion or the phenotypic programming of CH mutant cells, thereby affecting atherosclerosis, is unknown. Here, in humans and mice and across mutations in Jak2, Tet2, Trp53 and Dnmt3a, we demonstrate mutation-dependent responses to sleep and exercise in CH and show that mutant cells are uniquely sensitive to lifestyle.
The forgotten organ that could predict how long you live
The forgotten organ that could predict how long you live A forgotten immune organ may be one of the strongest hidden predictors of longevity, disease risk, and cancer treatment success. - Date: - June 1, 2026 - Source: - Mass General Brigham - Summary: - A long-overlooked organ may hold surprising clues to healthy aging and cancer survival.
This new diabetes pill burns fat without the downsides of Ozempic
This new diabetes pill burns fat without the downsides of Ozempic - Date: - June 3, 2026 - Source: - Karolinska Institutet - Summary: - Scientists have developed an experimental diabetes and obesity pill that works in a completely different way from drugs like Ozempic. Rather than reducing hunger, it activates metabolism in skeletal muscle, helping lower blood sugar and increase fat burning while preserving muscle mass. Early clinical results suggest the treatment is safe and well tolerated.